StockWatch: Investors Shrug as FDA Weighs First Gene-Edited Therapy

被引：0
|
作者：
Philippidis A.
机构：
来源：
Genetic Engineering and Biotechnology News | 2023年 / 5卷 / 01期
关键词：
Compendex;
D O I：
10.1089/genedge.5.1.85
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：436 / 439
页数：3
相关论文
共 50 条
  • [41] Orkambi® and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue
    Molinski, Steven V.
    Ahmadi, Saumel
    Ip, Wan
    Ouyang, Hong
    Villella, Adriana
    Miller, John P.
    Lee, Po-Shun
    Kulleperuma, Kethika
    Du, Kai
    Di Paola, Michelle
    Eckford, Paul D. W.
    Laselva, Onofrio
    Huan, Ling Jun
    Wellhauser, Leigh
    Li, Ellen
    Ray, Peter N.
    Pomes, Regis
    Moraes, Theo J.
    Gonska, Tanja
    Ratjen, Felix
    Bear, Christine E.
    EMBO MOLECULAR MEDICINE, 2017, 9 (09) : 1224 - 1243
  • [42] ECONOMIC EVALUATION OF EXAGAMGLOGENE AUTOTEMCEL (EXA-CEL) GENE-EDITED THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA
    Udeze, C.
    Fang, H.
    Ogunsile, F. J.
    Mujumdar, U.
    Nie, X.
    Yang, H.
    Jeyakumar, S.
    Li, N.
    Zhao, J.
    Lopez, A.
    VALUE IN HEALTH, 2023, 26 (06) : S1 - S1
  • [43] Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies (vol 116, pg 11978, 2019)
    Borot, Florence
    Wang, Hui
    Ma, Yan
    Jafarov, Toghrul
    Raza, Azra
    Ali, Abdullah Mahmood
    Mukherjee, Siddhartha
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (29) : 14780 - 14781
  • [44] ECONOMIC EVALUATION OF EXAGAMGLOGENE AUTOTEMCEL (EXA-CEL) GENE-EDITED THERAPY IN PATIENTS WITH SICKLE CELL DISEASE WITH RECURRENT VASO-OCCLUSIVE CRISES
    Udeze, C.
    Xie, Y.
    Ogunsile, F. J.
    Mujumdar, U.
    Yang, H.
    Chen, X.
    Jeyakumar, S.
    Li, N.
    Wang, J.
    Lopez, A.
    VALUE IN HEALTH, 2023, 26 (06) : S91 - S91
  • [45] FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections
    Asher Mullard
    Nature Reviews Drug Discovery, 2023, 22 : 610 - 610
  • [46] FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2023, 22 (08) : 610 - 610
  • [47] IDENTIFICATION OF TISSUE-SPECIFIC PROPERTIES OF HUMAN MESENCHYMAL STROMAL CELLS (HMSCS) TOWARDS DEVELOPING A SCALABLE MANUFACTURING PROCESS OF GENE-EDITED CELL THERAPY PRODUCTS
    Couto, P. Silva
    Stibbs, D. J.
    Rafiq, Q. A.
    CYTOTHERAPY, 2022, 24 (05) : S66 - S66
  • [48] Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa
    Khan, Afsheen
    Riaz, Rumaisa
    Ashraf, Saad
    Akilimali, Aymar
    ANNALS OF MEDICINE AND SURGERY, 2023, 85 (12): : 6298 - 6301
  • [49] Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl
    Bennett, Jean
    Maguire, Albert M.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2023, 13 (05):
  • [50] Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease
    Singh, Ajeet
    Irfan, Hamza
    Fatima, Eeshal
    Nazir, Zainab
    Verma, Amogh
    Akilimali, Aymar
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (08): : 4555 - 4559
12345